Drug Controller General of India Inaugrates Fermish Clinical Technologies

(PRLEAP.COM) Fermish Clinical Technologies Pvt. Ltd was inaugurated by Dr. M. Venkateswaralu, Drug Controller General of India on 10th September 2007, at the company office (Okhla Industrial Area, New Delhi).

“Its in a away to opportunity to do service, and the infrastructure is aptly provided” , scribbled Dr. M. Venkateswaralu on the comment book at launch and inauguration party of Fermish Clinical technologies Pvt. Ltd on 10th September 2007,at the company office (Okhla Industrial Area, New Delhi)

Fermish Clinical technologies Pvt. Ltd was inaugurated by Dr.M.Venkateswaralu, Drug Controller General of India on 10th September 2007,at the company office (Okhla Industrial Area, New Delhi)

The ceremony was much of a jamboree with succession of festive vibes and was followed by sumptuous dinner at Sheraton Hotel at Saket, New Delhi .

The guest invitees includes many eminent personalities from the industry. Accompanied by company Managing Director and the guest invitees , Dr. Venkateswaralu perambulated the facility and company premises after the formal ceremony of cutting the ribbon.

Fermish Clinical technologies Pvt. Ltd. is a company which promises to provide end-to-end services to CRO and pharmaceutical company worldwide. The company specializes in Clinical Trials Management Services, Regulatory Affairs, IVRS Based Services in Clinical Research, Clinical Research Contract Management, IT Services in Clinical Research and e- learning in Clinical Research.

More to say about company, it is headed by Mr. Khalid Khan, a veteran with over 17 years of experience as regulatory consultant, is based at Okhla Industrial Area in New Delhi. Dr. Khan is a consultant with a number of leading pharmaceutical companies.

The event was witnessed by several eminent reporters in science journalism.

For more details and Photographs, Visit:
http://www.fermish.com
mail: s.junaid@fermish.com

PR Leap is a service of Condesa, Inc. © 2009 All Rights Reserved. Use of our service is governed by our Privacy Policy and Terms of Service.
Issuers of news releases are solely responsible for the accuracy of their content. Copyright / IP Policy